Satoshi Mochida

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 5

Top Venues

PloS one

This page only lists publications with an associated author ORCID identifier.

Publications

Shinpei Yamaba, Yukinori Imai, Kayoko Sugawara, Yoshihito Uchida, Akira Fuchigami, Hiroshi Uchiya, Nobuaki Nakayama, Satoshi Mochida
Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma. PloS one 19 (4) (2024)
Shinpei Yamaba, Yukinori Imai, Kayoko Sugawara, Yoshihito Uchida, Akira Fuchigami, Hiroshi Uchiya, Nobuaki Nakayama, Satoshi Mochida
Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma. PloS one 19 (4) (2024)
Yoshihito Uchida, Masamitsu Nakao, Shunsuke Yamada, Shohei Tsuji, Hayato Uemura, Jun-Ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog. PloS one 17 (2) (2022)
Manabu Nakazawa, Yukinori Imai, Kayoko Sugawara, Yoshihito Uchida, Yoichi Saitoh, Yohei Fujii, Hiroshi Uchiya, Satsuki Ando, Nobuaki Nakayama, Tomoaki Tomiya, Satoshi Mochida
Long-term outcomes of patients with cirrhosis presenting with bleeding gastric varices. PloS one 17 (3) (2022)
Yoshihito Uchida, Kayoko Naiki, Jun-Ichi Kouyama, Kayoko Sugawara, Masamitsu Nakao, Daisuke Motoya, Mie Inao, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida
Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy. PloS one 13 (10) (2018)

Satoshi Mochida.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Satoshi Mochida